Trial Profile
An Exploratory phase II Study of Eribrin rechallenge after short term therapy of 5-FU for HER2 negative, advanced/recurrent breast cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Gimeracil/oteracil/tegafur
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 01 Oct 2021 Results published in the Anticancer Research
- 09 Nov 2020 Status changed from recruiting to active, no longer recruiting.
- 03 Oct 2020 Results presented at the Official 12th European Breast Cancer Conference